The deal brings both the injectable and oral versions of Wegovy straight to employers, another move in the push for workplace GLP-1 coverage.
Recap by typeshit. Full story at StreetInsider.
Obesity specialist Dr. Alexandra Sowa says long-term use makes cost the flashpoint, as insurers and employers scale back coverage and Medicare benefits face a 2027 question.
With 30% of covering employers weighing cuts, Wegovy and Zepbound users should check their plans now. Includes current self-pay prices and tips for appeals.
Endpoints News
Endpoints News reports Lilly's direct-to-patient sales model, built on Americans paying hundreds a month, is now becoming part of its plans overseas.
West Pharmaceutical shares are up about 20% since CNBC flagged the valuation in August, and the latest earnings give it reasons to expect further gains.
The BMJ reports that the person leading the UK government's national programme for trialling new obesity treatments has received nearly £80, with the full figure behind the link.
On his podcast, the NHS GP says studies show hunger hormones bounce back within four weeks, and he cites research on regaining about 60% of lost weight in a year.
Loading…